01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
23:08 , May 1, 2019 |  BC Extra  |  Company News

Caris aims to bridge gap between patients, precision trials with Pharmatech takeout

Caris' acquisition of Pharmatech, announced Wednesday, will allow the molecular profiling company to offer patients, physicians and drug developers an integrated approach to identifying and enrolling patients with rare mutations and other biomarkers in precision...
23:12 , Apr 24, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
03:35 , Jun 16, 2018 |  BioCentury  |  Product Development

MATCH’s long game

Although three of the first four arms in NCI-MATCH missed their endpoints, the results suggest the basket trial is doing what it is supposed to -- finding efficacy signals in rare cancers. It’s also yielded...
18:52 , Mar 15, 2018 |  BC Innovations  |  Tools & Techniques

Shared burden

Having learned their lesson with PD-L1, companies are collaborating on assay standards for tumor mutation burden -- a likely contender for the next major biomarker in immuno-oncology. A Friends of Cancer Research-led consortium of pharmas...
19:20 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Photo-activated, tumor-targeted nanoparticles could be used to deliver cancer therapies. The nanoparticles consist of an internal core of dodecyne lipids to enhance stability and enable cancer cell endocytosis, conjugated to an outer layer...
18:58 , Oct 27, 2017 |  BC Week In Review  |  Company News

John Wayne Cancer Institute joins Caris' Precision Oncology Alliance

John Wayne Cancer Institute (Santa Monica, Calif.) joined the Precision Oncology Alliance, which was established by Caris Life Sciences Inc. (Irving, Texas) to study tumor profiling and develop standards of care for molecular testing in...
21:13 , Jan 27, 2017 |  BC Week In Review  |  Company News

Caris, Lustgarten deal

Caris and the foundation partnered to conduct a Phase II trial of melanoma drug Keytruda pembrolizumab in patients with microsatellite unstable tumors. Caris is responsible for trial enrollment, and Lustgarten will provide funding. The partners...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Caris Life Sciences, Threshold deal

Caris and Threshold partnered to develop a companion diagnostic for Threshold’s evofosfamide using Caris’ ADAPT biotargeting system. Evofosfamide is a hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM). Late last year, the...